Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Diabetes & Obesity Care Operating Profit

Diabetes & Obesity Care Operating Profit % Chg.

Rare Disease Operating Profit

Rare Disease Operating Profit % Chg.

Total EBIT

Total EBIT Common Size

Total EBIT % Chg.

US Revenue

US Revenue % Chg.

EUCAN Revenue

EUCAN Revenue % Chg.

Emerging Markets Revenue

Emerging Markets Revenue % Chg.

APAC Revenue

APAC Revenue % Chg.

China Revenue

China Revenue % Chg.

Total International Revenue

Total International Revenue % Chg.

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

US Revenue (Pre-FY2024 Reporting)

US Revenue (Pre-FY2024 Reporting) % Chg.

Other North American Operations (NAO) Revenue

Other North American Operations (NAO) Revenue % Chg.

Total North American Operations (NAO) Revenue

Total North American Operations (NAO) Revenue % Chg.

EMEA Revenue

EMEA Revenue % Chg.

China Revenue (Pre-FY2024 Reporting)

China Revenue (Pre-FY2024 Reporting) % Chg.

Rest of World Revenue

Rest of World Revenue % Chg.

Rybelsus Revenue

Rybelsus Revenue % Chg.

Ozempic Revenue

Ozempic Revenue % Chg.

Victoza Revenue

Victoza Revenue % Chg.

Total GLP-1 Revenue

Total GLP-1 Revenue % Chg.

Long-Acting Insulin Revenue

Long-Acting Insulin Revenue % Chg.

Premix Insulin Revenue

Premix Insulin Revenue % Chg.

Fast-Acting Insulin Revenue

Fast-Acting Insulin Revenue % Chg.

Human Insulin Revenue

Human Insulin Revenue % Chg.

Total Insulin Revenue

Total Insulin Revenue % Chg.

Other Diabetes Care Revenue

Other Diabetes Care Revenue % Chg.

Total Diabetes Care Revenue

Total Diabetes Care Revenue % Chg.

Wegovy Revenue

Wegovy Revenue % Chg.

Saxenda Revenue

Saxenda Revenue % Chg.

Total Obesity Care Revenue

Total Obesity Care Revenue % Chg.

Diabetes & Obesity Care Revenue

Diabetes & Obesity Care Revenue % Chg.

Rare Blood Disorders Revenue

Rare Blood Disorders Revenue % Chg.

Rare Endocrine Disorders Revenue

Rare Endocrine Disorders Revenue % Chg.

Other Rare Disease Revenue

Other Rare Disease Revenue % Chg.

Rare Disease Revenue

Rare Disease Revenue % Chg.

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
Rybelsus Revenue	855.9	892.5
Ozempic Revenue	4,835.3	5,020.7
Victoza Revenue	86.3	144.3
Total GLP-1 Revenue	5,777.5	6,057.6
Long-Acting Insulin Revenue	660.6	705.3
Premix Insulin Revenue	370.7	416.2
Fast-Acting Insulin Revenue	646.2	717.1
Human Insulin Revenue	208.7	173.8
Total Insulin Revenue	1,886.2	2,012.4
Other Diabetes Care Revenue	66.2	71.7
Total Diabetes Care Revenue	7,729.9	8,141.7
Wegovy Revenue	3,201.2	3,083.2
Saxenda Revenue	118.3	133.3
Total Obesity Care Revenue	3,319.5	3,216.5
Diabetes & Obesity Care Revenue	11,049.4	11,358.2
Rare Blood Disorders Revenue	459.1	488.8
Rare Endocrine Disorders Revenue	219.1	224.2
Other Rare Disease Revenue	64.3	63.6
Rare Disease Revenue	742.5	776.7
Total Revenue	11,791.9	12,134.8

Revenue by Geography	Sep '25	Jun '25
US Revenue	6,470.9	6,783.4
EUCAN Revenue	2,637	2,596.8
Emerging Markets Revenue	1,043.5	1,191.1
APAC Revenue	859.7	886.5
China Revenue	780.7	677
Total International Revenue	5,320.9	5,351.5
Total Revenue by Geography	11,791.9	12,134.8

Revenue by Geography	Sep '25	Jun '25
US Revenue (Pre-FY2024 Reporting)	2,637	6,783.4
Other North American Operations (NAO) Revenue	—	—
Total North American Operations (NAO) Revenue	—	—
EMEA Revenue	—	—
China Revenue (Pre-FY2024 Reporting)	780.7	677
Rest of World Revenue	—	—
Total Revenue by Geography	780.7	677

EBIT	Sep '25	Jun '25
Diabetes & Obesity Care Operating Profit	3,809.5	5,199.4
Rare Disease Operating Profit	-84.9	81.8
Total EBIT	3,724.6	5,281.2